AR096045A1 - Composición farmacéutica y formulación para prevenir o tratar el síndrome de ojo seco - Google Patents
Composición farmacéutica y formulación para prevenir o tratar el síndrome de ojo secoInfo
- Publication number
- AR096045A1 AR096045A1 ARP140101650A ARP140101650A AR096045A1 AR 096045 A1 AR096045 A1 AR 096045A1 AR P140101650 A ARP140101650 A AR P140101650A AR P140101650 A ARP140101650 A AR P140101650A AR 096045 A1 AR096045 A1 AR 096045A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- dry eye
- eye syndrome
- formulation
- prevent
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 title abstract 3
- 206010013774 Dry eye Diseases 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- ALLWOAVDORUJLA-UHFFFAOYSA-N Rebamipida Chemical compound C=1C(=O)NC2=CC=CC=C2C=1CC(C(=O)O)NC(=O)C1=CC=C(Cl)C=C1 ALLWOAVDORUJLA-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000000443 aerosol Substances 0.000 abstract 1
- 239000000839 emulsion Substances 0.000 abstract 1
- 239000003889 eye drop Substances 0.000 abstract 1
- 229940012356 eye drops Drugs 0.000 abstract 1
- 239000007903 gelatin capsule Substances 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 229950004535 rebamipide Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 235000020357 syrup Nutrition 0.000 abstract 1
- 239000006188 syrup Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Una composición farmacéutica oral para prevenir o tratar el síndrome de ojo seco, la cual comprende rebamipida o una prodroga de la misma, o una sal farmacéuticamente aceptable de la misma, como un ingrediente activo. Los compuestos pueden tratar el síndrome de ojo seco a través de la vía oral, y pueden ser entonces empleados de manera segura y conveniente en comparación con las gotas para ojos convencionales. Reivindicación 2: La composición farmacéutica de la reivindicación 1, caracterizada porque la prodroga se selecciona a partir del grupo que consiste en los compuestos de fórmula química (1) a (6). Reivindicación 10: La formulación farmacéutica de la reivindicación 9, caracterizada porque está en la forma de polvo, gránulos, comprimidos, suspensiones, emulsiones, jarabes, aerosoles, o cápsulas de gelatina blandas o duras.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130043141A KR101692578B1 (ko) | 2013-04-18 | 2013-04-18 | 레바미피드 또는 이의 전구체를 포함하는 안구건조증의 예방 또는 치료를 위한 경구용 약제학적 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR096045A1 true AR096045A1 (es) | 2015-12-02 |
Family
ID=51731606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140101650A AR096045A1 (es) | 2013-04-18 | 2014-04-21 | Composición farmacéutica y formulación para prevenir o tratar el síndrome de ojo seco |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11712414B2 (es) |
| EP (1) | EP2987491B1 (es) |
| JP (1) | JP6249194B2 (es) |
| KR (1) | KR101692578B1 (es) |
| CN (1) | CN105142637B (es) |
| AR (1) | AR096045A1 (es) |
| AU (1) | AU2014254621B2 (es) |
| BR (1) | BR112015026332B1 (es) |
| CA (1) | CA2909806C (es) |
| ES (1) | ES2813649T3 (es) |
| IL (1) | IL242143B (es) |
| MX (1) | MX2015014672A (es) |
| MY (1) | MY183526A (es) |
| PH (1) | PH12015502406A1 (es) |
| RU (1) | RU2632107C2 (es) |
| SA (1) | SA114350449B1 (es) |
| TW (1) | TWI535441B (es) |
| WO (1) | WO2014171748A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101692578B1 (ko) * | 2013-04-18 | 2017-01-03 | 삼진제약주식회사 | 레바미피드 또는 이의 전구체를 포함하는 안구건조증의 예방 또는 치료를 위한 경구용 약제학적 조성물 |
| KR101764377B1 (ko) | 2017-03-22 | 2017-08-02 | 주식회사 메디컬오 | 천연 추출물을 포함하는 안구건조증 치료제 |
| CN109134533B (zh) * | 2017-06-27 | 2020-08-11 | 维眸生物科技（上海）有限公司 | 一种含磷化合物及其制备和应用 |
| EP3668836A4 (en) | 2017-08-18 | 2021-04-07 | The Schepens Eye Research Institute, Inc. | DRY EYE TREATMENT COMPOSITIONS AND METHODS OF APPLYING THEREOF |
| KR101840256B1 (ko) * | 2017-09-21 | 2018-03-21 | 대우제약 주식회사 | 레바미피드를 함유하는 새로운 안구건조증 치료용 점안 조성물 및 이의 가용화 및 안정화 방법 |
| KR101923519B1 (ko) | 2018-06-26 | 2019-02-27 | 대우제약 주식회사 | 레바미피드를 함유하는 안구 건조증 치료용 수용성 다회용 점안제 조성물 및 이의 가용화 및 안정화 방법 |
| KR20200019451A (ko) | 2018-08-14 | 2020-02-24 | 대우제약 주식회사 | 레바미피드를 함유하는 안구 건조증 치료용 수용성 다회용 점안제 조성물 및 이의 가용화 및 안정화 방법 |
| KR102190019B1 (ko) * | 2018-10-23 | 2020-12-15 | 삼진제약주식회사 | 쇼그렌 증후군 예방 또는 치료용 조성물 |
| CN114404379B (zh) * | 2022-01-29 | 2024-01-26 | 杭州沐源生物医药科技有限公司 | 一种瑞巴派特缓释片及其制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR004214A1 (es) | 1995-10-12 | 1998-11-04 | Otsuka Pharma Co Ltd | Una preparación de gotas oftálmicas para la cura de enfermedades oftálmicas |
| JP3093661B2 (ja) | 1995-10-12 | 2000-10-03 | 大塚製薬株式会社 | 眼疾患治療剤 |
| TWI363626B (en) | 2004-11-15 | 2012-05-11 | Otsuka Pharma Co Ltd | Aqueous ophthalmic suspension of crystalline rebamipide |
| ES2366375T3 (es) * | 2005-02-22 | 2011-10-19 | Pfizer, Inc. | Derivados de oxiindol, como agonistas del receptor 5-ht4. |
| ES2389566T3 (es) * | 2005-05-17 | 2012-10-29 | Santen Pharmaceutical Co., Ltd. | Agente preventivo o terapéutico para tratar un transtorno de la córnea y la conjuntiva |
| WO2008074853A1 (en) * | 2006-12-21 | 2008-06-26 | Novartis Ag | Ophthalmic rebamipide solution |
| US20090131303A1 (en) * | 2007-11-16 | 2009-05-21 | Bor-Shyue Hong | Methods and compositions for treating dry eye |
| EP2276508A4 (en) * | 2008-04-15 | 2011-12-28 | Sarcode Bioscience Inc | ADMINISTRATION OF LFA-1 ANTAGONISTS TO THE GASTROINTESTINAL SYSTEM |
| US8080562B2 (en) * | 2008-04-15 | 2011-12-20 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
| JP2009301866A (ja) | 2008-06-13 | 2009-12-24 | Panasonic Corp | プラズマディスプレイパネルの製造方法 |
| TWI495634B (zh) * | 2008-06-19 | 2015-08-11 | Otsuka Pharma Co Ltd | 醫藥組成物 |
| SA113340675B1 (ar) * | 2012-06-26 | 2015-08-16 | استيش. كو.، ليمتد | أدوية ريباميبايد تحضيرية جديدة، طريقة تحضيرها واستخدامها |
| KR101692578B1 (ko) * | 2013-04-18 | 2017-01-03 | 삼진제약주식회사 | 레바미피드 또는 이의 전구체를 포함하는 안구건조증의 예방 또는 치료를 위한 경구용 약제학적 조성물 |
-
2013
- 2013-04-18 KR KR1020130043141A patent/KR101692578B1/ko active Active
-
2014
- 2014-04-15 TW TW103113708A patent/TWI535441B/zh not_active IP Right Cessation
- 2014-04-17 MX MX2015014672A patent/MX2015014672A/es unknown
- 2014-04-17 JP JP2016508869A patent/JP6249194B2/ja not_active Expired - Fee Related
- 2014-04-17 CA CA2909806A patent/CA2909806C/en active Active
- 2014-04-17 SA SA114350449A patent/SA114350449B1/ar unknown
- 2014-04-17 ES ES14785310T patent/ES2813649T3/es active Active
- 2014-04-17 US US14/784,956 patent/US11712414B2/en active Active
- 2014-04-17 AU AU2014254621A patent/AU2014254621B2/en not_active Ceased
- 2014-04-17 EP EP14785310.5A patent/EP2987491B1/en not_active Not-in-force
- 2014-04-17 RU RU2015146417A patent/RU2632107C2/ru active IP Right Revival
- 2014-04-17 BR BR112015026332-1A patent/BR112015026332B1/pt not_active IP Right Cessation
- 2014-04-17 MY MYPI2015703685A patent/MY183526A/en unknown
- 2014-04-17 WO PCT/KR2014/003329 patent/WO2014171748A1/ko not_active Ceased
- 2014-04-17 CN CN201480022068.8A patent/CN105142637B/zh not_active Expired - Fee Related
- 2014-04-21 AR ARP140101650A patent/AR096045A1/es unknown
-
2015
- 2015-10-16 PH PH12015502406A patent/PH12015502406A1/en unknown
- 2015-10-18 IL IL242143A patent/IL242143B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CA2909806C (en) | 2020-04-21 |
| TW201442710A (zh) | 2014-11-16 |
| BR112015026332B1 (pt) | 2022-05-03 |
| JP6249194B2 (ja) | 2017-12-20 |
| EP2987491B1 (en) | 2020-06-03 |
| RU2632107C2 (ru) | 2017-10-02 |
| MY183526A (en) | 2021-02-24 |
| JP2016520566A (ja) | 2016-07-14 |
| EP2987491A1 (en) | 2016-02-24 |
| AU2014254621A1 (en) | 2015-11-19 |
| IL242143B (en) | 2021-03-25 |
| PH12015502406A1 (en) | 2016-02-22 |
| RU2015146417A (ru) | 2017-05-24 |
| US11712414B2 (en) | 2023-08-01 |
| US20160081922A1 (en) | 2016-03-24 |
| ES2813649T3 (es) | 2021-03-24 |
| BR112015026332A2 (pt) | 2017-07-25 |
| EP2987491A4 (en) | 2016-12-28 |
| AU2014254621B2 (en) | 2017-06-08 |
| WO2014171748A1 (ko) | 2014-10-23 |
| TWI535441B (zh) | 2016-06-01 |
| SA114350449B1 (ar) | 2016-05-08 |
| CN105142637A (zh) | 2015-12-09 |
| CA2909806A1 (en) | 2014-10-23 |
| MX2015014672A (es) | 2016-02-19 |
| KR20140125230A (ko) | 2014-10-28 |
| CN105142637B (zh) | 2021-08-17 |
| KR101692578B1 (ko) | 2017-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR096045A1 (es) | Composición farmacéutica y formulación para prevenir o tratar el síndrome de ojo seco | |
| TR201904455T4 (tr) | Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları. | |
| DOP2018000273A (es) | Compuestos químicos | |
| AR090456A1 (es) | Combinaciones farmaceuticas que comprenden un analogo de tionucleotidos | |
| UY36275A (es) | Compuestos aminopirimidinilo | |
| MX2016005394A (es) | Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4. | |
| EA201692249A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| EA201790202A1 (ru) | Фталазиноны и изохинолиноны в качестве ингибиторов rock | |
| MX382991B (es) | Inhibidores de la arginina metiltransferasa y usos de los mismos. | |
| MX386542B (es) | Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen. | |
| EA201891063A1 (ru) | Производные дигидроимидазопиразинона, применимые в лечении рака | |
| BR112016001678A2 (pt) | Composição, método de fabricação de um comprimido, comprimido, forma de dosagem unitária, artigo de fabricação, e, uso de uma composição, de um comprimido ou de uma forma de dosagem unitária | |
| CL2015001279A1 (es) | Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras. | |
| EA201692266A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| DOP2015000170A (es) | Compuestos químicos | |
| EA201790276A1 (ru) | Новые имидазопиридазиновые соединения и их применение | |
| PE20151607A1 (es) | Formulaciones de compuestos organicos | |
| EP2871187A4 (en) | A NEW CONNECTION OR PHARMACEUTICALALLY SALT AND PHARMACEUTICAL COMPOSITION THEREFOR AS AN ACTIVE SUBSTANCE | |
| EA201650003A1 (ru) | Соединённые циклоалкилом дигетероциклические производные | |
| BR112015023078A2 (pt) | inibidores de pirrolopirimindina cdk9 quinase | |
| WO2015002755A3 (en) | Compounds for the treatment of malaria | |
| PH12015502717B1 (en) | Anti-fibrogenic compounds, methods and uses thereof | |
| MX2017013103A (es) | Metodos para el tratamiento de trastornos cardiovasculares. | |
| EA201792676A1 (ru) | Ингибиторы jak1 | |
| AR100175A1 (es) | Inhibidores de autotaxina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |